Andersen T, Hyldstrup L, Quaade F
Int J Obes. 1983;7(5):423-30.
To evaluate the effect of the popular use of formula diets in the treatment of moderate obesity two regimens have been standardized: (1) formula diet replacing three of five daily meals (partial meal replacement (PMR, 1000 kcal (4.19 MJ] and (2) formula diet taken as five pre-meals (pre-meal satiation, PMS greater than or equal to 565 kcal (greater than or equal to 2.37 MJ]. Weight loss and compliance have been evaluated in a prospective 12 weeks randomized clinical trial with allocation to one of the two regimens or to a control group treated with a 1000 kcal (4.19 MJ) conventional diet (CD). CD and PMR were supported by diethylpropion (Dobesin) individually dosaged by the patient. No anorexic drugs was given to the PMS-group. Of 136 consecutively admitted patients 120 were included. After 12 weeks the median weight loss was 7.0, 8.4 and 6.1 kg in the CD-, PMR- and PMS-group, respectively (no significant differences between the groups (P much greater than 0.02]. Thirteen percent dropped out. Consumption of diethylpropion was significantly lower in the PMR-group compared with the CD-group (median 0.15 and 0.60 tablets of 25 mg per d, respectively). Even among selected sub-groups only few subjects obtained a relevant weight loss through continued treatment after the initial 12 weeks. No serious side-effects to the treatments were observed.
为评估常用配方饮食治疗中度肥胖的效果，已制定了两种标准化方案：（1）用配方饮食替代每日五餐中的三餐（部分代餐，PMR，1000千卡（4.19兆焦））；（2）在五餐前食用配方饮食（餐前饱腹感，PMS，大于或等于565千卡（大于或等于2.37兆焦））。在一项为期12周的前瞻性随机临床试验中，对体重减轻和依从性进行了评估，将患者随机分配至两种方案之一或接受1000千卡（4.19兆焦）传统饮食（CD）治疗的对照组。CD组和PMR组分别由患者自行服用己基间苯二酚（多贝斯因）。PMS组未给予厌食药物。在连续收治的136例患者中，纳入了120例。12周后，CD组、PMR组和PMS组的体重减轻中位数分别为7.0、8.4和6.1千克（组间无显著差异（P远大于0.02））。13%的患者退出。与CD组相比，PMR组的己基间苯二酚消耗量显著较低（中位数分别为每日0.15片和0.60片25毫克片剂）。即使在选定的亚组中，在最初的12周治疗后，只有少数受试者通过持续治疗实现了显著的体重减轻。未观察到治疗的严重副作用。
